New pill shows promise for rare joint tumor in Late-Stage trial
NCT ID NCT05804045
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether the drug Pimicotinib (ABSK021) can shrink tumors and improve symptoms in people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in joints that cannot be surgically removed. About 94 adults will receive either the drug or a placebo for 24 weeks, followed by open-label treatment. The main goal is to see how many patients respond with tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pimicotinib (ABSK021)
What this could lead to
If it works, this could offer a new treatment option for people with TGCT that cannot be removed by surgery, potentially shrinking tumors and easing symptoms.
What could go wrong
This is a relatively small Phase 3 trial, and the drug may not prove more effective than placebo. Side effects are possible, and long-term benefits are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, China
-
Duke University Medical Center
Durham, California, 27710, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hunan Provincial People's Hospital
Changsha, Hunan, China
-
IRCCS Istituto Ortopedico Rizzoli
Bologna, Italy
-
Leiden University Medical Center
Leiden, 2333, Netherlands
-
Liaoning Cancer Hospital&Institute
Shenyang, Liaoning, China
-
Maria Sklodowska-Curie National Research Institute of Oncology
Warsaw, Poland
-
McGill University Health Center
Montreal, Canada
-
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China
-
Ospedale di Prato
Prato, Italy
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
Precision NextGen Oncology
Beverly Hills, California, 90212, United States
-
Princess Margaret Cancer Center
Toronto, Canada
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
-
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Enshi, Hubei, China
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
-
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
-
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
-
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
-
Weifang People's Hospital
Weifang, Shandong, China
-
West China Hospital Sichuan University
Chengdu, Wuhan, China
-
Xi'an Honghui Hospital
Xi’an, Shanxi, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China